# heart failure with preserved ejection fraction FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/heart-failure-with-preserved-ejection-fraction

> 2 upcoming FDA catalysts in heart failure with preserved ejection fraction: edg-15400 25 mg (EWTX) on December 2027 (primary completion); edg-15400 25 mg (EWTX) on Dec 2027 to Mar 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| 1H 2026 | [Edg-15400 25 mg topline data readout](https://sec-api.dev/pdufa/edg-15400) | EWTX | heart failure with preserved ejection fraction | scheduled | "The Company expects top-line results from this study in the first half of 2026 and to initiate a Phase 2 trial in participants with heart failure with preserved ejection fraction (HFpEF) in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/tm266859d1_ex99-1.htm)) |
| 2H 2026 | [Edg-15400 25 mg trial start](https://sec-api.dev/pdufa/edg-15400) | EWTX | heart failure with preserved ejection fraction | scheduled | "EDG-15400, our second cardiovascular product candidate, is currently in a Phase 1 trial in healthy adults, with a future disease target of heart failure with preserved ejection fraction, and we expect to initiate a Phase 2 trial in the second half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1710072/000110465926091670/ewtx-20260630x10q.htm)) |
| December 2027 | [Edg-15400 25 mg primary completion](https://sec-api.dev/pdufa/edg-15400) | EWTX | Heart Failure With Preserved Ejection Fraction | scheduled | "NCT07795814 (A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07795814)) |
| Dec 2027 to Mar 2028 | [Edg-15400 25 mg topline data readout](https://sec-api.dev/pdufa/edg-15400) | EWTX | Heart Failure With Preserved Ejection Fraction | scheduled | "NCT07795814 (A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07795814)) |

## Drugs

- [Edg-15400 25 mg](https://sec-api.dev/pdufa/edg-15400) (EWTX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/heart-failure-with-preserved-ejection-fraction.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "heart failure with preserved ejection fraction FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/heart-failure-with-preserved-ejection-fraction

```bibtex
@misc{secapidev_indications_heart_failure_with_preserved_ejection_fraction_20261116,
  title        = {heart failure with preserved ejection fraction FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/heart-failure-with-preserved-ejection-fraction}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_heart_failure_with_preserved_ejection_fraction_20261116","title":"heart failure with preserved ejection fraction FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/heart-failure-with-preserved-ejection-fraction","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
